Table 2 Baseline characteristics of patients who received thrombolytic treatment by outcome groups
From: Interleukin-10 facilitates the selection of patients for systemic thrombolysis
Poor outcome (n = 81) | Good outcome (n = 103) | p | |
|---|---|---|---|
Age, years | 71.4 ± 9.3 | 64.3 ± 13.5 | <0.0001 |
Male gender, % | 54.3 | 61.2 | 0.370 |
Time from stroke onset, minutes | 84.7 ± 36.4 | 102.9 ± 83.8 | 0.234 |
TOAST | 0.095 | ||
- Atherothrombotic, n (%) | 16.0 | 13.6 | |
- Cardioembolic, n (%) | 59.3 | 49.5 | |
- Lacunar, n (%) | 0 | 5.8 | |
- Undetermined, n (%) | 24.7 | 31.1 | |
History of hypertension, n (%) | 59.3 | 50.5 | 0.297 |
History of diabetes, n (%) | 12.3 | 9.7 | 0.637 |
History of dyslipemia, n (%) | 21.0 | 32.0 | 0.099 |
Smoking history, n (%) | 14.8 | 12.6 | 0.672 |
Alcohol consumption, n (%) | 6.2 | 9.7 | 0.429 |
History of coronary disease, n (%) | 11.1 | 12.6 | 0.822 |
History of atrial fibrillation, n (%) | 35.8 | 25.2 | 0.145 |
Previous stroke or TIA, n (%) | 14.8 | 8.7 | 0.245 |
Systolic blood pressure, mmHg | 159.1 ± 24.4 | 155.6 ± 27.6 | 0.327 |
Diastolic blood pressure, mmHg | 86.7 ± 16.5 | 83.5 ± 15.1 | 0.180 |
Body temperature, °C | 36.2 ± 2.3 | 36.4 ± 0.4 | 0.218 |
Glucose levels, mg/dL | 129.5 ± 32.2 | 126.3 ± 40.0 | 0.142 |
Leukocytes, 103/mL | 8.2 ± 2.3 | 8.7 ± 2.9 | 0.349 |
Platelets, 103/mL | 223.6 ± 64.0 | 247.3 ± 86.7 | 0.086 |
Fibrinogen, mg/dL | 433.7 ± 114.7 | 412.6 ± 138.3 | 0.069 |
NIHSS at admission | 18 [14, 20] | 11 [7, 16] | <0.0001 |
DWI volume at admission, mL | 56.0 ± 60.2 | 16.7 ± 20.2 | <0.0001 |
MTT volume at admission, mL | 143.2 ± 87.4 | 72.3 ± 79.9 | <0.0001 |
Neuron-specific enolase (ng/mL) | 23.8 ± 7.4 | 22.4 ± 7.2 | 0.202 |
Interleukin-10 (pg/mL) | 12.9 ± 10.7 | 25.1 ± 17.9 | <0.0001 |
Tumor necrosis factor-α (pg/mL) | 13.8 ± 8.7 | 16.7 ± 11.5 | 0.057 |
Interleukin-6 (pg/mL) | 21.1 ± 17.3 | 14.8 ± 9.9 | 0.002 |
Active metalloproteinase-9 (ng/mL) | 27.8 ± 17.7 | 22.6 ± 12.1 | 0.026 |
Glutamate (μM) | 212.7 ± 147.5 | 171.4 ± 152.6 | 0.065 |